Pamela Lee, LPN - Licensed Practical Nurse in Mandan, ND

Provider's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

News Archive

Scientists to develop methotrexate nose drops for brain cancer

Scientists are reporting the development and successful initial testing of a new form of methotrexate the mainstay anticancer drug designed to be given as nose drops rather than injected. It shows promise as a more effective treatment for brain cancer, they say. The report appears in ACS' Molecular Pharmaceutics, a bi-monthly journal.

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

Researchers discover new way to disarm harmful bacteria

Rather than trying to kill bacteria outright with drugs, Université de Montréal researchers have discovered a way to disarm bacteria that may allow the body's own defense mechanisms to destroy them. "To understand this strategy one could imagine harmful bacteria being like Darth Vader, and the anti-virulence drug would take away his armor and lightsaber," explained Dr. Christian Baron, the study's lead author and Professor at the Department of Biochemistry.

Women, girls must be at center of water, food security efforts

Noting "World Water Week recently concluded in Stockholm with a special emphasis on the linkages between water and food security," Lakshmi Puri, assistant secretary-general and deputy executive director of U.N. Women, writes in this Inter Press Service opinion piece, "Creating a water- and food-secure world requires putting women and girls at the center of water- and food-related policies, actions and financing."

Alimera receives FDA CRL for ILUVIEN NDA

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced that Alimera Sciences, Inc, pSivida's collaborative partner, received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ILUVIEN. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

Read more News

› Verified 3 days ago